Post by Coultreon Biopharma

Press Release ǀ O3R-5671 Pharmacokinetic and pharmacodynamic data to be presented at ECCO and dosing in final cohort in first-in-human study initiated We are delighted with the progress since September! O3R-5671 has been safe and well tolerated to date, and a protocol amendment has been approved that will allow the exploration of higher doses in SAD and MAD cohorts. Read the full press release: https://lnkd.in/e45NY-Km And discover our poster presented at ECCO: https://lnkd.in/e-w4_nNd